A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).

PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is essential for maturation of ribosomes, may have a role in lipogenesis, and is implicated in several diseases. A potent, selective, and cell-active PRMT3 inhibitor would be a valuable tool for further investigating PRMT3 biology. Here we report the discovery of the first PRMT3 chemical probe, SGC707, by structure-based optimization of the allosteric PRMT3 inhibitors we reported previously, and thorough characterization of this probe in biochemical, biophysical, and cellular assays. SGC707 is a potent PRMT3 inhibitor (IC50 =31±2 nM, KD =53±2 nM) with outstanding selectivity (selective against 31 other methyltransferases and more than 250 non-epigenetic targets). The mechanism of action studies and crystal structure of the PRMT3-SGC707 complex confirm the allosteric inhibition mode. Importantly, SGC707 engages PRMT3 and potently inhibits its methyltransferase activity in cells. It is also bioavailable and suitable for animal studies. This well-characterized chemical probe is an excellent tool to further study the role of PRMT3 in health and disease.

[1]  R. Copeland,et al.  Small molecule control of chromatin remodeling. , 2014, Chemistry & biology.

[2]  M. Schapira,et al.  Structural biology and chemistry of protein arginine methyltransferases , 2014, MedChemComm.

[3]  J. Gustafsson,et al.  PRMT3 Regulates Hepatic Lipogenesis Through Direct Interaction With LXRα , 2014, Diabetes.

[4]  Amber L. Couzens,et al.  (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells , 2014, Proceedings of the National Academy of Sciences.

[5]  S. Frye,et al.  Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. , 2013, Journal of medicinal chemistry.

[6]  Robert A. Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery , 2013 .

[7]  Jian Jin,et al.  An allosteric inhibitor of protein arginine methyltransferase 3. , 2012, Structure.

[8]  C. Arrowsmith,et al.  Fluorescence-Based Methods for Screening Writers and Readers of Histone Methyl Marks , 2012, Journal of biomolecular screening.

[9]  P. Thompson,et al.  Activity-based protein profiling of protein arginine methyltransferase 1. , 2011, ACS chemical biology.

[10]  R. Copeland,et al.  Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. , 2011, Analytical biochemistry.

[11]  M. Bedford,et al.  Histone arginine methylation , 2011, FEBS letters.

[12]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[13]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[14]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[15]  M. Carmo-Fonseca,et al.  Hsp70 Chaperones and Type I PRMTs Are Sequestered at Intranuclear Inclusions Caused by Polyalanine Expansions in PABPN1 , 2009, PloS one.

[16]  Frank Herrmann,et al.  Human protein arginine methyltransferases in vivo – distinct properties of eight canonical members of the PRMT family , 2009, Journal of Cell Science.

[17]  S. Clarke,et al.  Protein arginine methylation in mammals: who, what, and why. , 2009, Molecular cell.

[18]  E. Wahle,et al.  Promiscuous Modification of the Nuclear Poly(A)-binding Protein by Multiple Protein-arginine Methyltransferases Does Not Affect the Aggregation Behavior* , 2008, Journal of Biological Chemistry.

[19]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[20]  K. Nagata,et al.  SET-mediated Promoter Hypoacetylation Is a Prerequisite for Coactivation of the Estrogen-responsive pS2 Gene by PRMT1* , 2006, Journal of Biological Chemistry.

[21]  Wladek Minor,et al.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.

[22]  H. Katus,et al.  Expression of nitric oxide related enzymes in coronary heart disease , 2006, Basic Research in Cardiology.

[23]  M. Person,et al.  Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3). , 2005, The Biochemical journal.

[24]  I. Newsham,et al.  DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo , 2004, Oncogene.

[25]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[26]  P. Silver,et al.  PRMT3 is a ribosomal protein methyltransferase that affects the cellular levels of ribosomal subunits , 2004, The EMBO journal.

[27]  E. Wahle,et al.  Unusual Sites of Arginine Methylation in Poly(A)-binding Protein II and in Vitro Methylation by Protein Arginine Methyltransferases PRMT1 and PRMT3* , 1999, The Journal of Biological Chemistry.

[28]  J. Tang,et al.  PRMT 3, a Type I Protein Arginine N-Methyltransferase That Differs from PRMT1 in Its Oligomerization, Subcellular Localization, Substrate Specificity, and Regulation* , 1998, The Journal of Biological Chemistry.

[29]  J. Rommens,et al.  Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy , 1998, Nature Genetics.

[30]  G. Perrault,et al.  A Comparative Study of the Effects of Selective and Non-Selective 5-HT2 Receptor Subtype Antagonists in Rat and Mouse Models of Anxiety , 1997, Neuropharmacology.

[31]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.